NGDC - GSA for Human

HRA007491

HRA007491.xlsx

Title:

Multi-analyte approach combining cfDNA sequencing and protein testing for early ovarian cancer detection (supplement)

Release date:

2025-05-03

Description:

We evaluated the feasibility and efficacy of a multi-analyte approach combining circulating tumor DNA (ctDNA) detection with protein biomarkers for early OC detection. At 95% specificity, predictive models using CA125 and ctDNA alone exhibited an overall sensitivity of 79.0% and 58.7%, respectively; however, when CA125 was combined with ctDNA, sensitivity reached 85.5%. Integrating CA125 and HE4 in the Risk of Ovarian Malignancy Algorithm (ROMA) index, yielded a sensitivity of 86.2%. When four additional proteins were added to CA125 and ctDNA in the EarlySEEK model, sensitivity increased to 94.2%. In patients with early-stage epithelial OC, CA125 alone yielded a sensitivity of 63.5%, whereas the sensitivities of the CA125+ctDNA, ROMA, and EarlySEEK models were 73.1%, 76.9%, and 90.4%, respectively. EarlySEEK was not affected by menopausal status, and outperformed CA125 and ROMA in distinguishing benign and malignant ovarian tumors in post-menopausal populations.

Data Accessibility:

Controlled access Request Data

BioProject:

PRJCA026407

Study type:

Disease Study

Disease name:

ovarian disease

Data Access Committee

For each controlled access study, there is a corresponding Data Access Committee(DAC) to determine the access permissions. Access to actual data files is not managed by NGDC.

DAC NO.:

HDAC004133

DAC name:

ZDFYCXD

Contact person:

Cheng Xiaodong

Email:

chengxd@zju.edu.cn

Description:

Team of Cheng

Aspera Command Line